An interventional study of Morning Bright Light Therapy and Negative Ion Generator in Traumatic Brain Injury, Post-traumatic Stress Disorder and Chronic Pain, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development — 8 open to participants now, 8 under way, none of them phase 3. Brain Injuries, Traumatic · VA Office of Research and Development.
Among the 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development, this one is the 10th largest by planned enrollment of the 46 interventional ones that give a count, is the only one that started in 2025, is one of 37 with no phase, and was the 52nd registered.
1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →8 of the 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18–65
VA Office of Research and Development · Sites in United States
Ages 22–65
VA Office of Research and Development · Sites in United States
Ages 18–65
VA Office of Research and Development · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is above the median of 52 across 1,091 interventional studies indexed under Brain Injuries, Traumatic.
Median enrollment 61 across the 46 interventional studies, 91 across the 9 observational. Of the 43 that completed or were terminated, 34 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
3 of the studies in Brain Injuries, Traumatic by VA Office of Research and Development that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02920788VA Office of Research and DevelopmentMild TBI Assessment & Rehabilitation | 2026-12-31 |
| NCT05776056VA Office of Research and DevelopmentMethylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints | 2027-03-31 |
| NCT04003285VA Office of Research and DevelopmentAllopregnanolone in Chronic Complex Traumatic Brain Injury | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The "polytrauma clinical triad" (PCT), a highly disabling constellation of factors, is defined by the coexistence of traumatic brain injury, post-traumatic stress disorder, and chronic pain. Veterans with the PCT are medically complex, often refractory to conventional therapies, and suffer from additional related chronic sequela. Notably, sleep disturbances and cognitive impairment, which the investigators hypothesize are significant contributing factors to these functional impairments and an impediment toward rehabilitation. Thus, the investigators' research aims to intervene "at the level of sleep", and by improving sleep, improve these interconnected, disabling, and difficult to treat enduring complexities associated with the PCT - ultimately to improve Veteran quality of life, functional independence, and restorative function. The investigators predict that the proposed intervention, morning bright light therapy, which is cost-effective, rapidly deployable and home-based, will be effective in improving sleep and overall PCT symptom management, thereby, resulting in a measurable and impactful improvement in quality of life.
The co-existence of traumatic brain injury, post-traumatic stress disorder (PTSD), and chronic pain defines the clinical entity referred to as the "polytrauma clinical triad" (PCT). Well recognized to be highly prevalent and disabling in US military service members and Veterans, those with the PCT are traditionally viewed as the most disabled cases and most refractory to conventional therapies. Central to the challenge in effectively treating Veterans with the PCT is the bi-directional, mutually reinforcing relationship between these conditions. Further complicating is the influence of sleep and cognitive impairment, both of which are widely regarded as primary contributing chronic sequela associated with the PCT. The specific contribution from sleep in exacerbating this clinical picture is supported by extensive scientific precedent demonstrating impairments in sleep intensify and worsen these related sequela (e.g., cognitive impairment, pain management, and PTSD symptom severity), which in turn, contribute to further impairment in sleep. Accordingly, an effective intervention targeting sleep may alleviate rehabilitative pressure on these associated sequelae and facilitate breaking out of this vicious cycle (i.e., poor sleep exacerbating outcomes, and in turn, further impairing sleep).
Recent work from the investigators' laboratory demonstrate promise for a simple, at home, non-pharmacologic and cost-effective, sleep focused intervention: morning bright light therapy (MBLT). The investigators have demonstrated robust feasibility, acceptability, and limited efficacy for MBLT to improve sleep, and thereby, improve cognitive function, PCT symptom management and overall quality of life in this medically complex and vulnerable population. Accordingly, this proposal aims to extend the foundational work from the CDA-2 to inform a prospective phase II placebo-controlled randomized clinical trial examining effectiveness for MBLT as a sleep- based intervention in Veterans with the PCT.
Specific aims designed to test this hypothesis are to determine effectiveness for MBLT to improve 1) sleep, 2) cognition, and 3) PCT symptom management in Veterans with the PCT. The investigators propose to enroll n=138 Veterans, randomized 2:1 to MBLT (10,000 lux light exposure for 60 min within 120 min of waking for 4-weeks) or a no- light sham-MBLT condition (as previously published using the same duration/timing). Sleep, cognition and PCT symptom management will be assessed through a novel combination of subjective/self-report, objective measures, and ecological momentary assessment sampling. Specific objective assessments include wrist- based actigraphy and as exploratory outcome in a sub-set of participants, home-based overnight polysomnography. Outcomes will be assessed pre- and post-intervention, with follow-up at 6- and 12-weeks post-intervention.
It is expected the proposed work will demonstrate effectiveness for MBLT to improve sleep, cognition, and PCT symptom management including ameliorating chronic pain and improving quality of life, in Veterans with the PCT. This project will demonstrate, 1) an effective treatment option, alone or in combination with existing rehabilitative efforts, in Veterans with the PCT, and 2) sleep-wake disturbances may be implicated in the pathogenesis of these functional impairments, thereby establishing greater precedent for targeting sleep as a meaningful primary and/or adjunctive rehabilitative therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 120 minutes of waking up.
Device: Morning Bright Light Therapy
Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 120 minutes of waking up.
Device: Negative Ion Generator
Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 120 minutes of waking up.
Also known as: Lightbox, light therapy
Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 120 minutes of waking up.
Sleep Efficiency via wrist based actigraphy
Sleep efficiency is defined by the total time asleep divided by total time spent in bed
Time frame: Pre- and post-4 weeks of MBLT or sham treatment
Self-reported sleep quality via the Pittsburgh Sleep Quality Index
The Pittsburgh Sleep Quality Index is a validated questionnaire assessing metrics related to sleep quality.
Time frame: Pre- and post-4 weeks of MBLT or sham treatment
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.
Of 445 non-industry interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 31 months is below that.
Counting every sponsor, half of 467 studies reached it within 41 months; a quarter within 22 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VA Office of Research and Development →